WHO ICTRP trial
Assessment of the effect of a chemotherapy combining two molecules in patients…
EUCTR2012-003592-19-BE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2012-003592-19-BE |
|---|---|
| Public title | Assessment of the effect of a chemotherapy combining two molecules in patients with operable, locally advanced or metastatic pancreas cancer |
| Scientific title | Evaluation of tumoral perfusion modification by dynamic imaging after chemotherapy combining gemcitabine and nab-paclitaxel (Abraxane) in patients with potentially operable, locally advanced or metastatic pancreatic adenocarcinoma - NEOPAX-001 |
| Primary sponsor | CUB Erasme Hospital |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Belgium |
| Conditions | Resectable (cohort 1) and locally advanced or metastatic (cohort 2) pancreatic ductal adenocarcinoma;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Trade Name: Abraxane Product Name: Abraxane Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: PACLITAXEL CAS Number: 33069-62-4 Concentration unit: mg/m2 milligram(s)/square meter Concentration type: equal… |
| Registration date | Oct 18, 2012 |
| Secondary IDs | NEOPAX-001 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: